Back to search
FDAFDA · Food and drugs·Recall number Z-2702-2017

Penumbra 3D Revascularization Device It is indicated for used in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral-M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Published July 26, 2017 · Recall initiated: June 9, 2017

Summary

FDA records medical device Class I recall Z-2702-2017, published July 26, 2017 and initiated June 9, 2017. Recalling firm: Penumbra Inc.; Status: Terminated; Reported quantity: 155 units; Lot: Lots C00644, C00645, C00646, C00717. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Penumbra Inc.
Distributor
Nationwide Distribution to the following states: AZ, CA, CO, FL, IN, MA, MI, MN, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WV
Lot
Lots C00644, C00645, C00646, C00717
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Penumbra 3D Revascularization Device It is indicated for used in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral-M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. recalled?

Yes. FDA published recall Z-2702-2017 on July 26, 2017. Reported hazard: Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.

What should I do if I have this product?

Voluntary: Firm initiated · Letter